source = Human recombinant
target = EGFR
CAS_number = 339177-26-3
ATC_prefix = L01
ATC_suffix = XC08
PubChem =
DrugBank =
C=6306 | H=9732 | N=1672 | O=1994 | S=46
molecular_mass= 147 kDa
bioavailability =
protein_bound =
metabolism =
excretion =
elimination_half-life = ∼7.5 days (range: 4-11 days)
pregnancy_category =
legal_status = Rx-only
routes_of_administration = intravenous

Panitumumab (INN), also ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as "EGF receptor", "EGFR", "ErbB-1" and "HER1" in humans).

Panitumumab is manufactured by Amgen and marketed as Vectibix.


It was FDA approved for the first time in September 2006, for the "the treatment of EGFR-expressing metastatic colorectal cancer with disease progression" despite prior treatment [" U. S. Food and Drug Administration" [] ] . Panitumumab was approved by the European Medicines Agency (EMA) in 2007, and by Health Canada in 2008 for the treatment of refractory EGFR-expressingmetastatic colorectal cancer in patients with non-mutated (wild-type) KRAS.


:mainarticle|epidermal growth factor receptorEGFR is a transmembrane protein.

Panitumumab works by binding to the extracellular domain of the EGFR (epidermal growth factor receptor) preventing its activation. This in turn, results in halting of the cascade of intracellular signals dependent on this receptor. [cite book |first=Jack W. |last=Plunkett |title=Plunkett's Biotech & Genetics Industry Almanac 2006 | publisher=Plunkett Research, Ltd. | date=September 30, 2005 |ISBN=1593920334 | accessdate=2006-10-20 | language=English ]


Panitumumab is produced by immunization of transgenic mice (xenomouse), that are able to produce human immunoglobulin light and heavy chains. After immunization of these animals a specific clone of B cells that produced an antibody against EGFR was selected and immortalized in Chinese hamster ovary (CHO) cells. These cells are then used for the full scale manufacture of the antibody.

Panitumumab vs. cetuximab

Although they both target the EGFR, panitumumab (IgG2) and cetuximab (IgG1) differ in their isotype and they might differ in their mechanism of action. Monoclonal antibodies of the IgG1 isotype may activate the complement pathway and mediate ADCC (antibody-dependent cellular cytotoxicity) better than their IgG2 counterparts, hence although they have not been documented, differences in the responses in treatments with these two antibodies might be expected. [ [ IgG1_IgG2 ] ]


Bevacizumab was the first fully human antibody to EGFR.Fact|date=September 2008


Further reading

Philippe Rougier, Emmanuel Mitry, Sophie Dominguez. Les Cancers Digestifs ; Springer , September 1, 2006, page=291 ; language=French

Wikimedia Foundation. 2010.

Look at other dictionaries:

  • Panitumumab — Masse/Länge Primärstruktur 144,3 kDa …   Deutsch Wikipedia

  • panitumumab — A human monoclonal antibody that is being used to treat colorectal cancer that has spread to other parts of the body. It is used in patients whose disease has not gotten better during or after treatment with other anticancer drugs. It is also… …   English dictionary of cancer terms

  • panitumumab — noun A human monoclonal antibody used in the treatment of some cancers …   Wiktionary

  • panitumumab — pani·tu·mu·mab (pan″ĭ tooґmə mab) an antagonist of epidermal growth factor receptors, used in treatment of metastatic colorectal carcinoma; administered by intravenous infusion …   Medical dictionary

  • Vectibix — Panitumumab Größe 144,3 kDa Bezeichner Externe IDs CAS …   Deutsch Wikipedia

  • Cetuximab — ? Monoclonal antibody Type Whole antibody Source Chimeric (mouse/human) Target EGF receptor Clinical data AHFS/ …   Wikipedia

  • Colorectal cancer — Classification and external resources Diagram of the lower gastrointestinal tract ICD 10 C …   Wikipedia

  • Monoclonal antibodies — A general representation of the methods used to produce monoclonal antibodies. Monoclonal antibodies (mAb or moAb) are monospecific antibodies that are the same because they are made by identical immune cells that are all clones of a unique… …   Wikipedia

  • Gemtuzumab ozogamicin — ? Monoclonal antibody Type Whole antibody Source Humanized (from mouse) Target CD33 Clinical data Trade names Mylotarg AHFS/ …   Wikipedia

  • Monoclonal antibody therapy — Each antibody binds only one specific antigen. Monoclonal antibody therapy is the use of monoclonal antibodies (or mAb) to specifically bind to target cells or proteins. This may then stimulate the patient s immune system to attack those cells.… …   Wikipedia

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”

We are using cookies for the best presentation of our site. Continuing to use this site, you agree with this.